144 related articles for article (PubMed ID: 28282648)
1. Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique.
Haidari LA; Brown ST; Constenla D; Zenkov E; Ferguson M; de Broucker G; Ozawa S; Clark S; Portnoy A; Lee BY
Sex Transm Dis; 2017 Apr; 44(4):222-226. PubMed ID: 28282648
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
3. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
4. The economic value of increasing geospatial access to tetanus toxoid immunization in Mozambique.
Haidari LA; Brown ST; Constenla D; Zenkov E; Ferguson M; de Broucker G; Ozawa S; Clark S; Lee BY
Vaccine; 2016 Jul; 34(35):4161-4165. PubMed ID: 27372153
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
6. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
9. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
10. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
11. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
[TBL] [Abstract][Full Text] [Related]
15. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
[TBL] [Abstract][Full Text] [Related]
16. Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach.
Tracy JK; Schluterman NH; Greene C; Sow SO; Gaff HD
Vaccine; 2014 May; 32(26):3316-22. PubMed ID: 24731734
[TBL] [Abstract][Full Text] [Related]
17. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
18. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
